托珠单抗治疗 COVID-19 急性呼吸窘迫综合征的全面综述
A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
机构信息
Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
J Clin Pharmacol. 2020 Sep;60(9):1131-1146. doi: 10.1002/jcph.1693. Epub 2020 Jul 27.
Abstract
Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19.
摘要
目前，世界正面临一种新型的贝塔冠状病毒的大流行，这种病毒被称为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。急性呼吸窘迫综合征（ARDS）是 SARS-CoV-2 最具破坏性的并发症。有研究表明，细胞因子释放综合征和主要的白细胞介素（IL）-6 在与新型 2019 年冠状病毒病（COVID-19）相关的 ARDS 的病理生理学中发挥着核心作用。尽管该疾病在全球范围内紧急，但目前尚无针对该疾病的经证实的治疗方法。托珠单抗是一种针对 IL-6 的潜在重组单克隆抗体，目前正在研究用于治疗 COVID-19 患者的 ARDS。鉴于这些情况，我们回顾了托珠单抗在治疗 COVID-19 相关 ARDS 方面的潜在治疗作用及其重要临床问题的现有证据。
相似文献
1
A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征的全面综述
J Clin Pharmacol. 2020 Sep;60(9):1131-1146. doi: 10.1002/jcph.1693. Epub 2020 Jul 27.
2
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.托珠单抗治疗 COVID-19 诱导的细胞因子风暴和急性呼吸窘迫综合征：来自宾夕法尼亚州西部农村一级创伤中心的病例系列。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.白细胞介素6抑制剂托珠单抗在日本新冠病毒相关急性呼吸窘迫综合征所致细胞因子释放综合征患者中的应用：病例系列
Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.
5
Repurposed Tocilizumab in Patients with Severe COVID-19.托珠单抗在重症 COVID-19 患者中的再利用。
J Immunol. 2021 Feb 1;206(3):599-606. doi: 10.4049/jimmunol.2000981. Epub 2020 Dec 9.
6
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.高剂量皮下注射阿那白滞素治疗重症 COVID-19 患者细胞因子风暴综合征继发急性呼吸窘迫综合征。
J Autoimmun. 2020 Dec;115:102537. doi: 10.1016/j.jaut.2020.102537. Epub 2020 Aug 20.
7
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.托珠单抗在 SARS-CoV-2 诱导的细胞因子风暴中的治疗作用：原理和现有证据。
Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059.
8
A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.新冠肺炎患者急性肺损伤/急性呼吸窘迫综合征应用促红细胞生成素作为辅助治疗的观点。
Arch Med Res. 2020 Oct;51(7):631-635. doi: 10.1016/j.arcmed.2020.08.002. Epub 2020 Aug 11.
9
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.托珠单抗治疗 COVID-19 中的“细胞因子风暴综合征”：一例报告。
Acta Med Indones. 2021 Apr;53(2):194-201.
10
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.病例报告：卡那奴单抗治疗 COVID-19 急性呼吸窘迫综合征患者。
Front Immunol. 2020 Aug 25;11:1942. doi: 10.3389/fimmu.2020.01942. eCollection 2020.
引用本文的文献
1
Immunomodulation in Respiratory Syncytial Virus Infection: Mechanisms, Therapeutic Targets, and Clinical Implications.呼吸道合胞病毒感染中的免疫调节：机制、治疗靶点及临床意义
Microorganisms. 2025 Aug 12;13(8):1876. doi: 10.3390/microorganisms13081876.
2
COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.合并慢性疾病患者、孕妇和哺乳期妇女中的新型冠状病毒肺炎：病理生理学、可用药物治疗以及每组最合适的方案疗程
Inflammopharmacology. 2025 Aug 12. doi: 10.1007/s10787-025-01829-4.
3
Calcio-herbal medicine Divya-Swasari-Vati demonstrates acceptable non-clinical safety profile in the repeated-dose 28-day subacute oral toxicity study in Sprague-Dawley rats, under GLP compliance.钙草药制剂Divya-Swasari-Vati在符合GLP规范的Sprague-Dawley大鼠重复给药28天亚急性经口毒性研究中显示出可接受的非临床安全性概况。
Front Pharmacol. 2025 Jun 17;16:1547532. doi: 10.3389/fphar.2025.1547532. eCollection 2025.
4
Effects of colchicine, interferon β, IVIG, tocilizumab and corticosteroids on COVID-19 patient survival from all presently available published clinical trials: A narrative review.秋水仙碱、干扰素β、静脉注射免疫球蛋白、托珠单抗和皮质类固醇对COVID-19患者生存的影响：基于所有现有已发表临床试验的叙述性综述。
Caspian J Intern Med. 2025 Mar 11;16(2):198-214. doi: 10.22088/cjim.16.2.198. eCollection 2025.
5
Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.Fcγ 受体 IIA 基因 rs1801274 及白细胞介素 6 受体基因 rs2228145 多态性对伊朗重症 COVID-19 患者接受托珠单抗治疗反应的影响。
BMC Infect Dis. 2024 Oct 16;24(1):1168. doi: 10.1186/s12879-024-10073-0.
6
A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection.关于微小RNA与病毒发病机制及感染之间相互作用的全面综述。
Med Res Rev. 2025 Mar;45(2):349-425. doi: 10.1002/med.22073. Epub 2024 Aug 26.
7
Scutellarein Suppresses the Production of ROS and Inflammatory Mediators of LPS-Activated Bronchial Epithelial Cells and Attenuates Acute Lung Injury in Mice.野黄芩苷抑制脂多糖激活的支气管上皮细胞中活性氧和炎症介质的产生，并减轻小鼠急性肺损伤。
Antioxidants (Basel). 2024 Jun 12;13(6):710. doi: 10.3390/antiox13060710.
8
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.托珠单抗对COVID-19患者的临床结局有影响吗？一项随机对照试验的荟萃分析。
J Pharm Policy Pract. 2023 Nov 20;16(1):151. doi: 10.1186/s40545-023-00662-w.
9
Aptamer-Based Strategies to Address Challenges in COVID-19 Diagnosis and Treatments.基于适配体的策略应对新冠病毒疾病诊断与治疗中的挑战
Interdiscip Perspect Infect Dis. 2023 Jul 31;2023:9224815. doi: 10.1155/2023/9224815. eCollection 2023.
10
A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系疾病现有和新兴治疗方法的临床处理方法。
Curr Neurol Neurosci Rep. 2023 Sep;23(9):489-506. doi: 10.1007/s11910-023-01287-x. Epub 2023 Aug 4.
本文引用的文献
1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.托珠单抗降低了 SARS-CoV-2 感染患者 ICU 入院和死亡的风险。
Rev Esp Quimioter. 2021 Jun;34(3):238-244. doi: 10.37201/req/037.2021. Epub 2021 Apr 7.
3
The immunology of COVID-19: is immune modulation an option for treatment?新型冠状病毒肺炎的免疫学：免疫调节是一种治疗选择吗？
Lancet Rheumatol. 2020 Jul;2(7):e428-e436. doi: 10.1016/S2665-9913(20)30120-X. Epub 2020 May 20.
4
Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.新冠肺炎肺炎 11 例危重症患者细胞因子释放综合征的定义和风险：疾病特征分析。
J Infect Dis. 2020 Oct 1;222(9):1444-1451. doi: 10.1093/infdis/jiaa387.
5
A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.一项回顾性对照队列研究，探讨糖皮质激素治疗对 SARS-CoV-2 感染死亡率的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01168-20.
6
Could ferritin help the screening for COVID-19 in hemodialysis patients?铁蛋白能否有助于血液透析患者的新型冠状病毒肺炎筛查？
Kidney Int. 2020 Jul;98(1):235-236. doi: 10.1016/j.kint.2020.04.017. Epub 2020 Apr 22.
7
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.全面更新的关于 SARS-CoV-2 和 COVID-19 的综述。
J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24.
8
Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis.预测严重 COVID-19 和入住重症监护病房的症状和合并症：系统评价和荟萃分析。
Int J Public Health. 2020 Jun;65(5):533-546. doi: 10.1007/s00038-020-01390-7. Epub 2020 May 25.
9
Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19.2013年欧洲轻至中度新冠肺炎患者的嗅觉和味觉丧失情况
Ann Intern Med. 2020 Oct 20;173(8):672-675. doi: 10.7326/M20-2428. Epub 2020 May 26.
10
Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19.COVID-19 住院患者的早期短程皮质类固醇治疗。
Clin Infect Dis. 2020 Nov 19;71(16):2114-2120. doi: 10.1093/cid/ciaa601.
Zotero 插件